NAD+/SIRT1 pathway regulates glycolysis to promote oxaliplatin resistance in colorectal cancer

Figure 4 CAY10602 enhances the sensitivity of resistant cells to oxaliplatin. A: MTS results after 24 hours of treatment of HCT116 Oxa-R cells with oxaliplatin (40 μM) alone, salermide (10 μM) alone, or oxaliplatin combined with salermide. ^bP < 0.01; B: MTS results after 24 hours of treatment of HCT116 Oxa-R cells with oxaliplatin (40 μM) alone, CAY10602 (20 μM) alone, or oxaliplatin combined with salermide. ^bP < 0.01; C: Colony formation assay confirmed the inhibitory effect of 14 days of treatment with oxaliplatin (40 μM) alone, CAY10602 (20 μM) alone, or oxaliplatin combined with salermide in HCT116 Oxa-R cells. ^bP < 0.01; ^dP < 0.0001; D-F: Effect of CAY10602 on oxaliplatin resistance in subcutaneously implanted HCT116 Oxa-R cells in a nude mouse model (1× 10⁶/mouse; n = 5/group). Tumors harvested from these nude mice were treated with saline (control), oxaliplatin alone (10 mg/kg, three times a week), CAY10602 alone (10 mg/kg, three times a week) or oxaliplatin together with CAY10602. The tumor volumes were quantified as V = L × W²/2 (where L is the length and W is the width). Tumors were harvested when the diameter was > 1.5 cm. ^dP < 0.0001.